779P - MicroRNAs expression in blood associated with taxanes response and overall survival in metastatic castration-resistant prostate cancer

Date 27 September 2014
Event ESMO 2014
Session Poster Display session
Topics Anti-Cancer Agents & Biologic Therapy
Prostate Cancer
Translational Research
Presenter Mercedes Marín-Aguilera
Citation Annals of Oncology (2014) 25 (suppl_4): iv255-iv279. 10.1093/annonc/mdu336
Authors M. Marín-Aguilera1, O. Reig2, G. Carrera3, L. Gaba Garcia2, N. Jiménez1, V. Pereira4, P. Gascon2, B. Mellado5
  • 1Translational Oncology Laboratory, Fundacio Clínic per a la Recerca Biomèdica, 08036 - Barcelona/ES
  • 2Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 3Medical Oncology, Hospital Plató, Barcelona/ES
  • 4Medical Oncology, Hospital Clinic Barcelona, 08028 - Barcelona/ES
  • 5Oncology Department, Hospital Clínic de Barcelona, Barcelona/ES

Abstract

Aim

MicroRNAs (miRs) are non-coding RNAs that regulate gene expression of several genes involved in cancer. Because their stability, these small molecules are potential to be blood-based markers for cancer diagnosis, staging, prognosis and response to treatment. The aim of this work was to analyze the prognostic and predictive role of circulating miRs as potential biomarkers of metastatic castration-resistant prostate cancer (mCRPC).

Methods

Peripheral blood from 87 mCRPC patients was collected. Fifty of them were obtained previously to chemotherapy treatment. The expression of 10 miRs selected from the literature as previously related to PC progression (miR21, miR34a, miR141, miR143, miR145, miR146a, miR205, miR221, miR222 and let7c) was analyzed at the mononuclear cells population by quantitative reverse transcriptase-polymerase chain reaction. Forty-three samples were analyzed in parallel for circulant tumor cells (CTC) count (CellSearch®). MiRs expression data were correlated with clinical characteristics, outcome, taxanes response and CTC count.

Results

MiR143 and miR34a were significantly overexpressed in patients with ≥ 5 CTCs (n = 20) in comparison with those with < 5 CTCs (n = 23) (P < 0.001). Overexpression of let7c, miR34a, miR145, miR143 and miR21 in peripheral blood correlated with worse overall survival in mCRPC patients according to Kaplan-Meier analysis (P < 0.05). Non-responders to taxanes chemotherapy showed higher expression of miR146a and miR let7c (P < 0.05).

Conclusions

This study suggests the utility of peripheral blood miRs detection as potential prognostic biomarker for mCRPC. Moreover, its association with chemotherapy response suggests a potential predictive value that needs to be further validated.

Disclosure

All authors have declared no conflicts of interest.